Insiders Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 19:20:00 13/02/2026 +03			5-day change	1st Jan Change
310.60 ^DKK	+1.32%		+5.11%	-4.50%

02-13	Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows	RE
02-13	Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US	FW

Insiders

02-12	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
02-10	Novo Says It's Suing Hims to Halt Obesity Drug Copycats	MT
02-09	Hims & Hers Stops Selling Wegovy Copycat Weight-Loss Pill	MT
02-09	Global markets live: Alphabet, Meta, Eli Lilly, Uber, Ocado…
02-09	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Data-Heavy Week	MT
02-09	Wall St struggles for direction as investors await key economic data	RE
02-09	PRESS DIGEST- New York Times business news - Feb 9	RE
02-04	Novo Nordisk plunges as its 2026 outlook rattles investors
02-04	Novo Nordisk CEO: The big uptake of the Wegovy pill more than justifies the reduced price	RE
02-04	Novo Nordisk CEO: We don't see our Wegovy pill price strategy as a gamble; we think it's our responsibility to be able to give all the people in need the medications that we are making	RE
02-04	Novo Nordisk CFO: Our price point in the U.S. for Wegovy is very close to compounders' price points	RE
02-04	Novo Nordisk CFO: We are looking at a percentage decline in 2026 U.S. sales in the "teens"	RE
02-04	Novo Nordisk CFO: 'Most-Favored Nation' Is a Meaningful Driver of Lower Prices in the U.S.; But the Bigger Driver Is Related to a Bigger Cash Business	RE
02-04	Novo Nordisk CFO: Our semeglutide patent in India expires in a few months; we expect more generic competition in India on the obesity drug market	RE
02-04	Novo Nordisk CFO tells Reuters: still very low penetration on the Chinese obesity drug market; competition there has been intense	RE
02-04	Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future	RE
02-04	Novo Nordisk CEO: We have no plans for systematic mass layoffs this year	RE
02-04	Novo Nordisk CEO: We expect to introduce new strategic aspirations as part of our Capital Markets Day	RE
02-04	Novo Nordisk Q4 media conference call ends	RE
02-04	Novo Nordisk CEO: Capital Markets Day to be held on Sept 21 in London	RE
02-04	Novo Nordisk CEO: Company is not in a crisis right now	RE
02-04	Novo Nordisk CFO: Some obese patients will prefer long-acting GLP-1s and that is clearly something the company is 'looking into'	RE
02-04	Novo Nordisk CFO: Obesity market is still in early stages of maturity, and will fragment over time in part due to very different preferences	RE
02-04	Novo Nordisk CFO: Medicare Part D coverage is included in our 2026 guidance	RE
02-04	Novo Nordisk CEO: We feel very confident that we can meet U.S. Wegovy pill demand	RE